Table of Content

1. Introduction to LAG-3 Inhibitor
1.1 Overview Of LAG-3 inhibitor
1.2 Mechanism of Action
1.3 LAG-3 Targeted Therapy Approaches


2. Global LAG-3 Inhibitor Clinical Trials Overview
2.1 By Phase
2.2 By Country
2.3 By Company
2.4 By Indication
2.5 By Priority Status
2.6 Patient Segment


3. Global LAG-3 Inhibitors Market Scenario
3.1 Current Market Outlook (2022 Till Q1’2024)
3.2 Future Market Outlook (2024 - 2029)


4. LAG-3 Inhibitor Market Regional Analysis
4.1 South Korea
4.2 Australia
4.3 Canada
4.4 Japan
4.5 UK
4.6 Europe
4.7 China
4.8 US


5. LAG-3 Inhibitor Market Development By Indications
5.1 Lymphoma
5.2 Melanoma
5.3 Lung Cancer
5.4 Colorectal Cancer
5.5 Head & Neck Cancer
5.6 Esophageal Cancer


6. Opdualag (Nivolumab & Relatlimab-rmbw) - Overview, Pricing, Dosing & Sales Analysis
6.1 Overview
6.2 Pricing & Dosing
6.3 Sales (2022 Till Q1’2024)


7. Combination Stratagems for LAG-3 Inhibitors


8. Global LAG-3 Inhibitors clinical Trials Insight By Company, Country, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III


9. Marketed LAG-3 Inhibitor Clinical insight


10. Global LAG-3 Inhibitors Market Dynamics
10.1 Market Drivers
10.2 Market Challenges


11. Competitive Landscape
11.1 Abeome Corporation
11.2 ABL Bio
11.3 Agenus
11.4 Akeso Biopharma
11.5 AnaptysBio
11.6 Bristol-Myers Squibb
11.7 EpimAb Biotherapeutics
11.8 F-star Therapeutics
11.9 Immutep
11.10 Incyte Corporation
11.11 Innovent Biologics
11.12 Merck
11.13 Roche
11.14 Shanghai Fosun Pharmaceutical
11.15 Y-Biologics



List of Tables

Table 3-1: China - Ongoing Clinical Trials for LAG-3 Inhibitors
Table 3-2: US - Some Ongoing Clinical Trials for LAG-3 Inhibitors

Table 4-1: Lymphoma – Some Ongoing Clinical Trials for LAG-3 Inhibitors
Table 4-2: Melanoma – Some Ongoing Clinical Trials for LAG-3 Inhibitors

Table 5-1: Opdualag - Maximum Infusion Volumes and Concentration Ranges by Patient Group
Table 5-2: Opdualag - Recommended Dosage Modifications for Adverse Reactions

Table 6-1: Ongoing Preclinical & Clinical trials for Combination of LAG-3 inhibitors